Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...
Adding an SGLT2 inhibitor to standard care did not improve clinical outcomes in critically ill patients with acute organ dysfunction, an open-label randomized trial involving intensive care units ...
Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...
In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...
NEW ORLEANS, LA—Ever since sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to have beneficial effects in patients with heart failure, there have been questions about the underlying ...
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below: Receive the the latest news, research, and presentations from major meetings ...
THE WOODLANDS, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of publications concluding that sotagliflozin’s differentiated dual SGLT1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback